2. Anti-infection
  3. SARS-CoV
  4. CIM-834

CIM-834 is an orally effective inhibitor of SARS-CoV-2 membrane protein. CIM-834 can prevent the assembly of infectious virus particles without inhibiting the synthesis of viral RNA. CIM-834 can reduce the viral titer in the lungs of SCID mice infected nasally with SARS-CoV-2, block the spread of SARS-CoV-2 among Syrian hamsters, and inhibit the replication of SARS-CoV-2 (including variants) and SARS-CoV. CIM-834 can be used in related research on COVID-19.

For research use only. We do not sell to patients.

CIM-834

CIM-834 Chemical Structure

CAS No. : 3104363-32-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

CIM-834 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CIM-834 is an orally effective inhibitor of SARS-CoV-2 membrane protein. CIM-834 can prevent the assembly of infectious virus particles without inhibiting the synthesis of viral RNA. CIM-834 can reduce the viral titer in the lungs of SCID mice infected nasally with SARS-CoV-2, block the spread of SARS-CoV-2 among Syrian hamsters, and inhibit the replication of SARS-CoV-2 (including variants) and SARS-CoV. CIM-834 can be used in related research on COVID-19[1].

In Vitro

CIM-834 (0-10 μM; 3-5 d) potently inhibits SARS-CoV and HCoV-OC43 replication, exhibits partial activity against HCoV-229E, and lacks activity against HCoV-NL63, FIPV, PEDV, and MERS-CoV[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CIM-834 Related Antibodies
Parmacokinetics
Species Dose Route Cmax AUC0-last Bioavailability
Mice[1] 10 mg/kg i.v. 1013 ng/mL 4714 ng·h/mL 57 %
Mice[1] 100 mg/kg p.o. 9889 ng/mL 91977 ng·h/mL 112 %
Golden hamster[1] 100 (with pre-treatment of 50 mg/kg Ritonavir) mg/kg p.o. 8640 ng/mL 54614 ng·h/mL /
In Vivo

CIM-834 (100 mg/kg; p.o.; once or twice daily for 3 consecutive days) reduces the titer of infectious SARS-CoV-2 in the lungs of SCID mice[1].
CIM-834 (100 mg/kg, p.o., twice daily for 4 days, in combination with ritonavir 50 mg/kg, p.o., twice daily) reduces lung SARS-CoV-2 titers in Syrian hamsters[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CB-17/Icr-Prkdcscid/scid/Rj SCID mice (male, 7-9 weeks old, intranasal infection with SARS-CoV-2 B.1.351)[1]
Dosage: 100 mg/kg (once daily; twice daily)
Administration: p.o.; once daily; 3 days; p.o.; twice daily; 3 days
Result: Significantly and dose-dependently reduced the infectious virus titer and viral RNA load in lung tissue.
Reduced the infectious virus titer in the mouse lungs by more than 3 log₁₀ within 48 hours administration after infection.
Animal Model: Syrian hamsters (female, 8-10 weeks old, intranasal infection with SARS-CoV-2 USA-WA1/2020)[1]
Dosage: 100 mg/kg (CIM-834); 50 mg/kg (ritonavir)
Administration: p.o.; twice daily; 4 days (CIM-834 co-administered with ritonavir)
Result: Reduced lung viral RNA levels by 3.4 log10 and infectious viral titres by greater than 4 log10.
Resulted in nearly normal lung parenchyma with only very focal perivascular inflammation.
Prevented transmission of SARS-CoV-2 from treated index hamsters to untreated sentinel hamsters.
Molecular Weight

494.68

Formula

C27H42N8O
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CC1=NC(N2CCC(N(C)C3=CC(C(NCCN4CCCC4)=O)=CN=N3)CC2)=NC(C)=C1CC(C)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (202.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0215 mL 10.1075 mL 20.2151 mL
5 mM 0.4043 mL 2.0215 mL 4.0430 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.05 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.05 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.0215 mL 10.1075 mL 20.2151 mL 50.5377 mL
5 mM 0.4043 mL 2.0215 mL 4.0430 mL 10.1075 mL
10 mM 0.2022 mL 1.0108 mL 2.0215 mL 5.0538 mL
15 mM 0.1348 mL 0.6738 mL 1.3477 mL 3.3692 mL
20 mM 0.1011 mL 0.5054 mL 1.0108 mL 2.5269 mL
25 mM 0.0809 mL 0.4043 mL 0.8086 mL 2.0215 mL
30 mM 0.0674 mL 0.3369 mL 0.6738 mL 1.6846 mL
40 mM 0.0505 mL 0.2527 mL 0.5054 mL 1.2634 mL
50 mM 0.0404 mL 0.2022 mL 0.4043 mL 1.0108 mL
60 mM 0.0337 mL 0.1685 mL 0.3369 mL 0.8423 mL
80 mM 0.0253 mL 0.1263 mL 0.2527 mL 0.6317 mL
100 mM 0.0202 mL 0.1011 mL 0.2022 mL 0.5054 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CIM-834 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CIM-8343104363-32-5CIM834CIM 834SARS-CoVSARS coronavirusSARS-CoV-2 membrane proteincovid-19HCoV-229ESyrian hamstersSARS-CoV-2 M_longHCoV-OC43SCID miceSARS-CoV-2SARS-CoV-2 M_shortInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CIM-834
Cat. No.:
HY-172760
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.